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Abstract
Biomarkers in predicting the progression of HIV infected individu-
als to a state of HIV disease (AIDS) are studied over more than a 
decade. Use of surrogate markers in the past for tracking clinical 
progression of the disease was limited, as little knowledge existed 
about the disease. The aim of this review was to address various 
changes in biomarker related studies taking place over the last five 
years, especially the trend towards use of newer biomarkers and ex-
perimentation with novel molecules in a quest for halting HIV dis-
ease progression. An open search of PUBMED database was made 
with search ‘key words’ such as ‘Biomarkers’ and ‘AIDS (Acquired 
Immunodeficiency Syndrome)’.The following were the inclusion 
criteria for articles: a) all articles published in English language, 
b) years of publication between 2002-2008 and c) articles limited 
to ‘adult’ population. This yielded a total of 417 articles. The cri-
teria used for further judging these studies considered a) type of 
research design, b) number of biomarkers studied, c) validity of 
the biomarkers, d) techniques to assess the biomarkers and the im-
pact of the studies in furthering biomarker research, e) sample size 
for the studies and f) article title or abstracts having the following 
key words ‘biomarker’ or ‘biomarkers’ and ‘predict progression to 
AIDS’. A total of 27 abstracts were reviewed and 12 studies met 
the above criteria. These 12 different studies consisted of three re-
views, four cohort designs, three cross-sectional designs, one each 
of an observational, and an in-vitro design. The various biomark-
ers emerging as a results were primarily a mix of viral, neural, im-
munological, HLA (human leukocyte antigen) markers along with 
lymphocyte counts. Although there have been quite a few advance-
ments in biomarker-related studies, majority of the novel biomark-
ers discovered need to be further evaluated and replicated in bigger, 
long-term efficacy trials. Efforts should also be made to discover 
newer genetic markers of disease progression. Biomarker feedback, 
a new concept, can be utilized in future studies addressing preven-
tion of HIV infection or halting disease progression.
Keywords:  Biomarkers; Progression; Designs; HIV; AIDS; Valid-
ity
Introduction
Acquired immunodeficiency syndrome or AIDS consists of a 
constellation of symptoms which are suggestive of end-stag-
es of human immunodeficiency virus (HIV) infection. This 
syndrome involves loss or decrease in immunity against cer-
tain non-threatening illnesses. The HIV infects certain cells 
of the immune system and can also directly infect brain [1]. 
Infected individuals are called HIV positive individuals but 
without AIDS. Most individuals progress from this state to-
wards the disease (AIDS) [2].
The pathogenesis of HIV infection involves series of 
dynamic interactions between the HIV virus and the host im-
mune cells, which results in a state of continuous immune 
activation throughout the course of the infection [3]. To as-
sess the biomarkers related to AIDS, we need to understand 
the spectrum of this disease, i.e., from getting infected with 
the HIV virus to developing full blown AIDS. A review ar-
ticle which looked at the immunological markers and sur-
rogate markers for predicting clinical progression from HIV 
infection to AIDS, was able to discuss the importance of 
markers such as β2 microglobulin [4-8], neopterin [9-11], 
sIL-2R [12, 13], sCD8 [14, 15], antibodies such as anti-p24 
[16, 17], antigp120 [18,19], anti-p17 [20], anti-gp41 [21], 
anti-nef [22, 1], anti-sCD4 [23], and anti-leucocyte antibod-
ies [24]. Some of the additional biomarkers studied in the 
past are antigen markers such as p24 antigens [25, 26], se-
rological markers such as tumor necrosis factor α [27, 28],   
acid-labile human leukocyte IFN (interferons), 2-5A syn-
thetase, percentage of CD4+ T-cells, absolute CD4+ T-cell 
numbers, and CD4+/CD8 T-cell ratio. It is clearly seen that 
there have been a plethora of biomarkers which have been 
studied which predict the progression of an HIV infected 
individual to a state of active disease of AIDS. Despite of 
having a large quantity of surrogate markers for the disease, 
their clinical use still remains debatable, as they fail to fulfill 
some of the important criteria like 1) having clear role in the 
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natural history of HIV-induced illness, 2) being detectable 
in the majority of infected individuals, 3) changing measur-
ably with clinical status in both progression and remission of 
disease and 4) changing quantifiably after a therapeutic in-
tervention or no change following failure of therapy. More-
over, very few studies have shown the effect of treatment on 
surrogate markers and long-term survival. There is a great 
need for validation of these studies in larger trials before sur-
rogate marker measurements would be accepted universally 
as clinical end-points [3].
Current research in the arena of biomarkers studies re-
lated to HIV/AIDS continues to be experimental and bereft 
of validated biomarkers. There is a shift in the cellular mark-
ers of disease progression from lymphocyte predominance to 
other cellular markers such as monocyte-macrophage system 
[29]. These preliminary experimental studies need to be fol-
lowed by more longitudinal studies which discover newer 
biomarkers which are associative as well as predictive of 
progression of disease. 
The following systematic literature review attempts to 
look at various studies conducted and published by HIV re-
searchers related to use of  biomarkers and its role in asso-
ciation or prediction of HIV infection or AIDS progression.
Methodology
An open search of PUBMED database was made with search 
‘key words’ such as ‘Biomarkers’ and ‘AIDS (Acquired Im-
munodeficiency Syndrome)’. There were 2533 hits with this 
search. The following were the inclusion criteria for articles: 
a) all articles published in English language, b) years of pub-
lication between 2002-2008 and c) articles limited to the 
‘adult’ population. This yielded a total of 417 articles. The 
criteria used for further judging these studies considered a) 
type of research design, b) number of biomarkers studied, 
c) validity of the biomarkers, d) techniques to assess the 
biomarkers and the impact of the studies in furthering bio-
marker research, e) sample size for the studies and f) article 
title or abstracts having the following key words ‘biomarker’ 
or ‘biomarkers’ and ‘predict progression to AIDS’.  A total 
of 27 abstracts were reviewed and 12 studies met the above 
criteria.
The Figure 1 is a summary of the study flow which states 
the progress through stages of the systematic review predict-
ing progression of HIV virus related disease.
Results
A summary of each study including the research design used, 
type of biomarkers studied the main outcomes of the study 
and relevant conclusions drawn are presented in Table 1. 
There were three review studies [40, 29, 43] which showed 
the importance of a) blood and cerebrospinal fluid markers 
such as CSF HIV 1 RNA and proviral HIV DNA, b) increase 
in macrophage makers and c) plasma viral HIV RNA, P24 
antigen and CD4 cell counts, as biomarkers of progression of 
HIV infection. Three cross-sectional studies [31-33] looked 
at C-reactive protein and HLA (Human leukocyte antigens 
and  soluble  toll-like  receptors  as  effective  biomarkers  of 
disease progression. This clearly shows the importance of 
immunological markers in the study of disease progression. 
There were four cohort studies [30, 34-36] which looked at 
immunoglobulin (IgG levels), neural markers such as sphin-
gomyelin, TLC (total lymphocyte count), hemoglobin, and 
the CD4 cell counts to determine disease progression.
An observational study [41] used cox proportional haz-
ards regression model to determine association between per-
cent CD4 and disease progression while an in-vitro study 
[42]  looked  at  regulatory T-cells  as  predictors  of  disease 
worsening. This study also showed a potential of developing 
new biomarkers by manipulating the regulatory T-cells.
Discussion
Biomarkers related to HIV infection or which predict the 
progress of HIV infection to AIDS are wide and varied. The 
trend in last 15 years in conducting biomarker studies has 
shown a shift from using immunological and surrogate mark-
Figure 1.  Progress through stages of systematic review of stud-
ies predicting progression of HIV virus related disease.
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ers such as β2-microglobulin [30, 5], neopterin [9, 10] and 
anti-leucocyte antibodies [24] to some newer markers such 
as sTLR2 (soluble toll-like receptors) [31], C-reactive pro-
tein [32] and HLA (human leukocyte antigen) markers [33]. 
Name of the 
study
Research design Biomarkers  Results/discussion Conclusions
1) 
Price et al 
(2007) [40]
Review Viral: CSF HIV 1 RNA, 
neuropathogenetic genotypes
Immunological: Beta 2 
microglobulin,neopterin, quinolinic 
acid, MCP-1
Neural: molecular products 
of neurons, astrocytes, 
oligodendrocytes, microglia.
Other: reactive aldehydes-4 
hydroxy-nonenal
Elevated CSF HIV 1 RNA along with 
raised MCP-1 or neopterin suggest 
AIDS-dementia complex or HIV -1 
encephalitis.
Proviral HIV DNA within peripheral 
blood mononuclear cells–prognostic 
marker for ADC (AIDS-dementia 
complex).
Monocytes showing increased 
expression of CD69, CD16, & TNF 
–alpha.
Combination of blood and CSF 
markers should be used.
Develop objective laboratory based 
quantitative measures for predicting 
and establishing diagnosis.
2) Gendelman 
(2007) [29]
Review Quinolinic acid, chemokines, 
proinflammatory cytokines, matrix 
metalloproteinases surrogates as 
well as causal.
End-stage disease dementia and 
encephalitis occurs due to blood-borne 
macrophage entry in brain. 
Micro arrays done showed increase in 
RANTES increase in chronic stage.
Miroglial-macrophage activation 
underlies many divergent 
neurodegenerative disorders 
including neuroaids.
There is further need of 
understanding host-defense as well 
as cell-signaling mechanisms.
3)
Hulgan et al 
(2007)
[41]
Observational 
study
Absolute CD4, percent CD4, and 
HIV 1-RNA
Used a cox proportional hazards 
regression model to determine 
associations between percent CD4 
and disease progression. Prior ART 
(p < 0.0001), injection drug use (p < 
0.04), lower absolute CD4 (p = 0.002), 
and lower percent CD4 (p = 0.002) 
predicted disease progression.
Percent CD4 at initiation of first 
HAART regimen predicted disease 
progression independent of absolute 
CD4. Percent CD4 may be used 
to determine timing of HAART 
(Highly active Antiretroviral 
therapy).
4) 
Nilsson et al 
(2006) [42]
In-vitro study T-reg cell numbers(specialized 
subset of CD4 cells), FOX P3, 
CTLA-4, IDO, TGF – β1(functional 
markers) 
Increased number of FOX P3 positive 
T-cells and increased expression of 
T-reg cell associated markers were 
detected only during progressive HIV 
disease.
T-reg cell exposure to HIV promoted 
their survival via CD4-gp 120 
dependent pathway.
T-reg cells accumulate due to 
increase in HIV viral load.
 They negatively affect the immune 
control of virus replication.
Potential novel ways of improving 
the immune function can be through 
manipulation of these T-reg cells.
5) 
Lau et al (2006) 
[32]
Cross-sectional 
study
C-reactive protein The association of log10CRP(C-reactive 
protein) were inversely correlated with 
CD4 lymphocyte counts (r = -0.17, p 
< 0.001) and directly with log10HIV 
RNA levels (r = 0.20, p < 0.001). Levels 
of CRP of  > 2.3 mg/l were associated 
with decreased time to AIDS (acquired 
immunodeficiency syndrome).
Levels of C-reactive protein were 
associated with HIV disease 
progression independent of CD4 
lymphocyte counts and HIV RNA 
levels.
6) 
Kiepala et al 
(2005) [43]
Review Viral markers: Plasma HIV RNA 
load, serum p24 antigen load, serum 
p 24 antibodies, syncitium inducing 
strains.
Surrogate markers: Anti-p27 nef
Immune markers: CD4 cell counts, 
percentage of CD4 cells, CD8 cell 
counts, neopterin, beta 2 micro 
globulin
Other markers:CCR5, HLA type 
and resistance genotyping and 
phenotyping.
Plasma viral load (HIV RNA) is 
most representative and sensitive 
laboratory test as a predictor of risk for 
disease progression and response to 
antiretroviral therapy.
P24 antigen was more specific, and 
cheaper but less sensitive.
CD4 cell counts should be followed 
longitudinally and percentage of 
CD4 cells more accurately predicts 
progression.
Various statistical tests have 
indicated that CD4 cells, serum 
level of B2 microglobulin and p24 
antigenemia in a descending order 
were best predictors of disease 
progression.
Host genetic factors may be 
incorporated in assessment in the 
future.
Table 1. Biomarkers Studies Related to HIV Infection or Acquired Immunodeficiency Syndrome (Review Year 2002-2008)
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There seems to be more research studies which are looking 
at neuropathogenic biomarkers predicting HIV infection of 
the central nervous system.
The biological basis for some of the newer markers (such 
as quinolinic acids, chemokines, and matrix metalloprotein-
ases) in neuropathogenic HIV disease is surrogates as well 
as causal agents [29]. Looking at other important biomark-
ers, β-2 microglobulin and neopterin indicate the degree of 
immunological activation, CD4+ T-helper cells which have 
prognostic and diagnostic importance and HIV-specific anti-
bodies whose decline is crucial in indicating prognosis of the 
disease [3]. The role of C-reactive protein in HIV pathogen-
esis is yet unclear [30] and rise in sphingomyelin, ceramides 
is due to oxidative stress which in turn is due to loss of cel-
Name of the 
study
 
Research design Biomarkers  Results/discussion Conclusions
7) 
Carbone et al 
(2004)
[30]
Retrospective 
cohort study using 
cox proportional 
hazards model.
Immunoglobulin 
levels 
High levels of soluble markers IgG (relative 
hazard (RH):1.06, p = 0.006), IgA (RH 1.67, p 
= 0.02), IgM (RH 1.28, p = 0.0001), B2-M (RH 
2.38, p < 0.0001) and sTNF-R (RH 1.07, p = 
0.002) individually showed progression to AIDS.
This is the first demonstration in a 
cohort of injection drug users that 
immunoglobulin level measurements 
have predictive value for HIV progression 
independent of CD4 T-cell counts and 
HIV RNA.
8) 
Heggelund 
et al (2004) 
[31]
Cross-sectional  sTLR 2- (soluble 
Toll-like 2 receptor) 
levels.
Chi-square analysis showed undetectable levels 
of sTLR 2 receptors in AIDS patients controlled 
with healthy controls (p = 0.02). No statistically 
significant correlation was found between sTLR 
levels and CD4 and CD8-T cell counts. HIV 
infected progressors to AIDS had decreased sTLR 
at all time points returned to baseline levels at last 
time point.
There is an association between sTLR 
levels and disease progression to AIDS. 
There can be an increased cytokine 
response to bacterial lipoproteins after 
sTLR levels depletion causing further 
progression of HIV disease.
9) 
Sacktor et al 
(2004) [34]
Cohort analysis Sphingomyelin, 
ceramide, 2- 
pentylpyrrole lysine 
adduct.
There was an increase in two HNE 
(hydroxynonenal) adducts in medial frontal, 
cerebellum and cerebrospinal fluid of HIV 
dementia patients.
Massive amounts of oxidative stress was seen 
with HIV encephalitis.
Spingomyelins were raised in inactive dementia 
cases compared to HIV + cases without dementia; 
ceramides were elevated in active dementia cases.
Sphingomyelin metabolic products and 
markers of oxidative stress such as HNE 
and ceramide are elevated in actively 
progressive dementia cases.
Surrogate markers must be correlated with 
clinical progression of HIV disease.
10) 
Fernandes 
et al (2003) 
[33]
Cross-sectional 
study
HLA-markers such as 
HLA- A1, A11, B8, 
B35, DR3, DR1, 
DQ2, DQ1, Bw4, 
B44, B57.
At least one of these HLA markers were exhibited 
by 56.4% of the patients associated with rapid 
progression to AIDS and 7.2% presented with at 
least one marker associated with slow progression 
to AIDS.
The frequency of markers associated with rapid 
progression to AIDS was significantly increased in 
patients with CMV(cytomegalovirus) retinitis in 
relation to those without retinitis
( P < 0.002) and 
HLA-markers associated with rapid 
progression to AIDS were significantly 
raised in CMV-retinitis group.
HLA-markers may simultaneously 
predispose to AIDS and CMV-retinitis.
11) 
Lau et al 
(2003) [35]
Prospective cohort 
study
Total lymphocyte 
count and hemoglobin 
concentration
A total lymphocyte decline greater than 10% and 
Hgb decline greater than 2.2% was present  in 
over 77% of HIV positive men who developed 
AIDS but only 23% of HIV positive who did not.
Both total lymphocyte count and 
hemoglobin concentration showed a 
period of stability which was followed by 
a rapid decline beginning before the onset 
of AIDS.
Hence these markers are useful in 
monitoring disease progression in 
resource limited setting.
12) 
Jacobson 
et al (2002) 
[36]
Cohort study CD4 lymphocyte cell 
counts.
Within 3.5 years of HAART (highly active 
antiretroviral therapy) initiation 11.3% of subjects 
developed AIDS and determinants of AIDS was a 
CD4 cell count of < 200cells/microl
(relative hazard = 2.25 95% CI = 1.13, 4.49). 
An increase in CD4 counts of 50microlit. 
Immediately after HAART initiation also 
improved prognosis (RH = 0.34, 95% CI = 0.16, 
0.71)
There is no difference between men who 
started HAART at a lower CD4 count and 
men who started HAART at a higher CD4 
count from the time point of progression 
to AIDS.
HIV RNA levels were good for prognosis 
but less informative in predicting death.
Table 1 (continued). Biomarkers Studies Related to HIV Infection or Acquired Immunodeficiency Syndrome (Review Year 2002-2008)
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lular homeostasis in HIV infection [34]. 
There  is  a  mix  of  cross-sectional,  cohort  and  review 
studies which attempt to study biomarkers predicting pro-
gression of the disease. Some of these studies were associa-
tive studies and need replication in bigger trials. Validation 
of these various biomarkers is the need of the hour as some 
of the studies reviewed were experimental. The assessment 
of biomarkers were for predicting and establishing diagnosis 
of acquired immunodeficiency syndrome, understanding the 
pathogenic process of disease progression and developing 
newer genetic and surrogate markers for understanding the 
disease process. Surrogate marker usage in the past and at 
present continues, as they have a potential for reducing the 
cohort size required to conduct such studies and the duration 
of each trial.
Although biomarkers are useful in predicting the sever-
ity and progression of the disease, they should always be 
correlated with clinical disease progression. In developing 
world where access to advanced biomarker detection tech-
niques is less, markers such as total lymphocyte count and 
hemoglobin concentration are useful in monitoring disease 
progression as shown in a prospective cohort study [35]. The 
past decade has seen extraordinary advancements in HIV 
therapy and with the advent of viral protease inhibitors in 
1995, has invited multi-drug combination protocols such as 
highly-active anti-retroviral therapy (HAART). The effect of 
the HAART in changing the immunological profile of HIV 
infected  individuals  showed  a  decrease  in  absolute  CD4, 
memory CD4 and naïve CD4 lymphocytes while a prospec-
tive study showed no difference in time to AIDS progression 
when CD4 cells were used as the biomarkers. Although CD4 
cells continue to be used as one of the best predictive bio-
markers for disease progression, a suggestion of using HIV 
RNA is made from prognostic point of view [36].
The uses of genetic biomarkers for predicting progres-
sion of the disease shows mixed evidence. An international 
meta-analysis, which tried to assess the role of CCR5 delta 
32 and CCR2-641 alleles on disease progression among pe-
diatric population, showed no protection over long term [37] 
while  another  meta-analysis  carried  out  in  United  States, 
Europe and Australia among adult population showed de-
creased risk of progression to AIDS and deaths [38]. Hence, 
it seems we need more studies to be fully convinced of the 
protective effects of these alleles in predicting HIV progres-
sion.
One of the ways of acquiring HIV infection is from in-
dulging in unsafe sexual practices. It would be helpful for us 
as researchers, to know if biomarkers and biomarker feed-
back can be effective in generating healthy behavior change 
as a primary prevention strategy. Biomarker feedback has 
been used to study various behaviors such as smoking ces-
sation, dietary change and increased physical activity with 
mixed results [39]. It can either make an individual moti-
vated and getting ready for a behavioral change, or cause 
immense  psychological  distress  and  adverse  behavioral 
changes. There is a need of additional research studies in 
these areas.
Conclusions
In conclusion, the last decade has shown some advances in 
biomarker definitions and techniques for biomarker assays. 
These need to be validated over long-term by replicating 
studies in larger trials and with different population groups. 
Some of the biomarkers discovered are still in their nascent 
stages and may prove to be useful in future. 
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